Loading...
XTSE
HLS
Market cap110mUSD
Dec 05, Last price  
4.86CAD
1D
-1.02%
1Q
-10.83%
Name

HLS Therapeutics Inc

Chart & Performance

D1W1MN
XTSE:HLS chart
P/E
—
P/S
1.95
EPS
—
Div Yield, %
—
Shrs. gr., 5y
1.63%
Rev. gr., 5y
0.89%
Revenues
57m
-10.23%
68,202,16949,661,118100,588,71068,147,08271,875,65688,098,90478,746,327116,555,59279,465,98773,877,12519,956,00054,031,00075,082,00061,415,00054,160,00056,109,00060,009,00061,467,00063,074,00056,619,000
Net income
-20m
L-28.61%
9,507,4901,310,0547,594,66802,553,719011,983,34916,867,2039,732,61812,717,29500-6,097,000-24,806,000-19,552,000-15,331,000-13,117,000-23,598,000-27,531,000-19,655,000
CFO
8m
-49.31%
12,500,430703,50021,977,1785,554,6425,323,27325,063,98917,918,70721,230,76318,031,12418,208,9140027,166,00032,747,00026,408,0009,344,00016,429,00016,942,00015,789,0008,003,000
Dividend
Apr 27, 20230.05 CAD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.
URL
https://www.hlstherapeutics.com/
IPO date
Mar 17, 1980
Employees
99
Domiciled in
CA
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT